The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 1 of the 16 sources its claims cite were checked for support.
Elevated sympathetic nerve activity in patients with accelerated essential hypertension.
Open accessAbstract
To determine if an abnormality exists in the sympathetic nervous system of patients with accelerated hypertension, we recorded muscle sympathetic nerve activity (MSNA) from the tibial nerve by microneurography in eight benign essential hypertensives and seven accelerated essential hypertensives. Basal MSNA, plasma renin activity, and plasma angiotensin II levels were significantly higher in accelerated hypertensives than in benign hypertensives (P < 0.05). To clarify the relationship between the renin-angiotensin axis and sympathetic nervous system in the accelerated hypertensives, we measured the MSNA after 7 d of oral administration of captopril (75 mg/d) for antihypertensive treatment in the benign hypertensives and accelerated hypertensives. After administering captopril, the arterial pressure decreased significantly in the benign hypertensives and accelerated hypertensives with decreases in plasma angiotensin II levels, and the decreases in arterial pressure were greater in the accelerated hypertensive than in the benign hypertensives. After captopril administration, the MSNA decreased significantly in the accelerated hypertensives but did not change in the benign hypertensives. Thus, in accelerated hypertensives, sympathetic tone is elevated, and the elevated sympathetic tone is closely related to the activated renin-angiotensin axis tone.
Overview
CoChat Summary
TL;DR
In accelerated essential hypertensives, basal muscle sympathetic nerve activity (MSNA), plasma renin activity, and plasma angiotensin II were significantly higher than in benign hypertensives. Captopril lowered blood pressure and angiotensin II in both groups but reduced MSNA only in accelerated hypertensives, suggesting elevated sympathetic tone is linked to renin-angiotensin axis activation.
Key findings
Basal MSNA was significantly higher in accelerated hypertensives than in benign hypertensives (P < 0.05).
- Basal plasma renin activity was 6.5±1.0 vs 1.4±0.3 ng ANG I·ml⁻¹·h⁻¹, and plasma angiotensin II was 59±5 vs 19±4 pg·ml⁻¹ in accelerated vs benign hypertensives (P < 0.05).
- Resting arterial pressure was higher in accelerated hypertensives: systolic 210±3 vs 161±4 mmHg and diastolic 126±3 vs 91±2 mmHg (P < 0.05).
- After 7 d of captopril (75 mg/d), plasma angiotensin II decreased significantly in both groups, arterial pressure decreased significantly in both groups, and the depressor response was greater in accelerated hypertensives. MSNA decreased significantly in accelerated hypertensives but did not change significantly in benign hypertensives.
Methods
Single-blind trial of placebo and captopril in eight benign essential hypertensives (four males, four females; 40±3 yr) and seven accelerated essential hypertensives (four males, three females; 39±2 yr).
- MSNA was recorded from the tibial nerve by microneurography; basal values were measured after 30 min supine rest, and captopril was then given orally for 7 d (75 mg/d).
- Plasma renin activity and plasma angiotensin II were measured by radioimmunoassay; arterial pressure, heart rate, and MSNA were compared using paired and unpaired Student’s t tests, with significance at P < 0.05.
- Captopril measurements were repeated in eight benign hypertensives and five of seven accelerated hypertensives.
Limitations
The paper does not state a formal limitations section.
- Evident from the text: the sample was small (8 benign and 7 accelerated hypertensives), and captopril follow-up included only 5 of 7 accelerated hypertensives.
- Evident from the text: there was no normotensive control group, treatment was short-term (7 d), and the design cannot establish causality between renin-angiotensin activation and elevated MSNA.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 5 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The activation of the renin-angiotensin axis is known to play a very important role in the pathogenesis and pathophysiology of accelerated or malignant hypertension (7, 8).”
- Also stated in: § Discussion · p. 3 · boosted
“The activation of renin-angiotensin axis is known to play a very important role in the pathogenesis of accelerated or malignant hypertension (7, 8).”
What the sources say
- Partly supportedcites [7] 7. Laragh, J. H., S. Ulick, W. Januszewicz, Q. B. Deming, W. G. Kelly, and S. Lieberman. 1960. Aldosterone secretion and primary and malignant hypertension. J. Clin. Invest. 39:1091-1106. sourceExperimental — accuracy not yet measured
The Summary reports elevated aldosterone secretion in 14 of 15 patients with malignant hypertension, supporting an association with the condition. The Discussion says aldosterone might contribute to the malignant syndrome but could also be a consequence of it. The paper does not establish activation of the renin–angiotensin axis or its important causal role (searched: renin, angiotensin, and pathogenesis). (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [8] 8. Rosset, E., J. R. Scherrer, and R. Veyrat. 1973. Increased plasma renin substrate concentration in human malignant hypertension. Helv. Med. Acta. 37:235-250.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · p. 3 · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MSNA decreased significantly in accelerated hypertensives, but did not change significantly in benign hypertensives (Fig. 2).”
- Also stated in: § Abstract · p. 1 · plain
“After captopril administration, the MSNA decreased significantly in the accelerated hypertensives but did not change in the benign hypertensives.”
plainn = 8- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · p. 1 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The MSNA decreased significantly in accelerated hypertensives, but did not change significantly in benign hypertensives (Fig. 2).”
- Also stated in: § Abstract · p. 1 · plain
“After captopril administration, the MSNA decreased significantly in the accelerated hypertensives but did not change in the benign hypertensives.”
plainstates a causen = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · p. 1 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Basal MSNA, plasma renin activity, and plasma angiotensin II levels were significantly higher in accelerated hypertensives than in benign hypertensives (P < 0.05).”
- Also stated in: § Results · p. 2 · plain
“The basal MSNA was significantly higher in the accelerated hypertensives than in the benign hypertensives (P < 0.05, Fig. 1).”
- Also stated in: § Discussion · p. 3 · plain
“The basal MSNA was greater in the accelerated hypertensives than in the benign hypertensives.”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · p. 2 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The heart rate in the accelerated hypertensives did not differ from that in benign hypertensives (Table I).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
12 more claims
Create a free account to see all 24 claims and to verify the 3 references still open.
- The quote only partly states this claim. 3
- Probably not a substantial claim. 3
- It may state two separate claims as one. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, the increased activity in EHT + LVH was not attributable to antihypertensive treatment and, in fact, was still apparent despite the use of agents”
From Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive (2001) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Also, treatment with angiotensin-converting enzyme inhibitors in hypertension has been shown to have either no effect or decrease sympathetic nerve traffic (31,32).”
From Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive (2001) · cites this paper as [32]
Citations
Cites
Anderson, E. A., Sinkey, C. A., Lawton, W. J., & Mark, A. L. (1989) · Hypertension · doi:10.1161/01.hyp.14.2.177 · Cited by 632
Evidence for a Central Mechanism in Angiotensin Induced Hypertension.
Bickerton, R. K., & Buckley, J. P. (1961) · Experimental Biology and Medicine · doi:10.3181/00379727-106-26492 · Cited by 387
Cardiovascular Effects of Angiotensin Mediated by the Central Nervous System
FERRARIO, C. M., GILDENBERG, P. L., & MCCUBBIN, J. W. (1972) · Circulation Research · doi:10.1161/01.res.30.3.257 · Cited by 353
ALDOSTERONE SECRETION AND PRIMARY AND MALIGNANT HYPERTENSION *
Laragh, J. H., Ulick, S., Januszewicz, V., Deming, Q. B., Kelly, W. G., & Lieberman, S. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104124 · Cited by 305
Adrenergic Facilitation by Angiotensin: Does it Serve a Physiological Function?
Zimmerman, B. G. (1981) · Clinical Science · doi:10.1042/cs0600343 · Cited by 255
Age-related changes in muscle sympathetic nerve activity in essential hypertension
Yamada, Y., Miyajima, E., Tochikubo, O., Matsukawa, T., & Ishii, M. (1989) · Hypertension · doi:10.1161/01.hyp.13.6.870 · Cited by 220
Self-citationEvidence that angiotensin enhances transmitter release during sympathetic nerve stimulation
HUGHES, J., & ROTH, R. H. (1971) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1971.tb08025.x · Cited by 197
The action of angiotensin and bradykinin on the superior cervical ganglion of the cat.
Lewis, G. P., & Reit, E. (1965) · The Journal of Physiology · doi:10.1113/jphysiol.1965.sp007679 · Cited by 187
Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans
Matsukawa, T., Gotoh, E., Minamisawa, K., Kihara, M., Ueda, S., Shionoiri, H., & Ishii, M. (1991) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1991.261.3.r690 · Cited by 113
Self-citationAugmented sympathetic nerve activity in response to stressors in young borderline hypertensive men
MATSUKAWA, T., GOTOH, E., UNEDA, S., MIYAJIMA, E., SHIONOIRI, H., TOCHIKUBO, O., & ISHII, M. (1991) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1991.tb09064.x · Cited by 97
Self-citation
Research works printed but not linked: 1
- [17]17. Wallin, B. G. 1983. Intraneural recording and autonomic function in man. In Autonomic Failure. R. Bannister, editor. Oxford University Press, London. pp. 36–51.
Cited by
Pescatello, L. S., Franklin, B. A., Fagard, R., Farquhar, W. B., Kelley, G. A., & Ray, C. A. (2004) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000115224.88514.3a · Cited by 1,872
“Muscle SNA was elevated in hypertensive subjects as compared with normotensive subjects in some (82,99,174,175) but not all studies (183,269).”
ResultHow to assess sympathetic activity in humans
Grassi, G., & Esler, M. (1999) · Journal of Hypertension · doi:10.1097/00004872-199917060-00001 · Cited by 455
Reduction of Sympathetic Hyperactivity by Enalapril in Patients with Chronic Renal Failure
Ligtenberg, G., Blankestijn, P. J., Oey, P. L., Klein, I. H. H., Dijkhorst-Oei, L.-T., Boomsma, F., Wieneke, G. H., van Huffelen, A. C., & Koomans, H. A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401704 · Cited by 409
Hermann, M., Flammer, A., & Lüscher, T. F. (2006) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.06032.x · Cited by 354
Blood flow restriction training and the exercise pressor reflex: a call for concern
Spranger, M. D., Krishnan, A. C., Levy, P. D., O'Leary, D. S., & Smith, S. A. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00208.2015 · Cited by 293
Metadata
- Authors
- Matsukawa, T., Mano, T., Gotoh, E., & Ishii, M.
- Affiliations
- Nagoya University (JP)
- Research Institute of Environmental Medicine, Nagoya University (JP)
- Yokohama City University (JP)
- ORCID
- Ishii, M
- Venue
- Journal of Clinical Investigation
- Published
- 1993-07-01
- Volume
- 92
- Issue
- 1
- Pages
- 25-28
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC293521
- OpenAlex
- W2023629143
- Cited by
- 94
- References
- 19
- Citations by year
- 2026: 1 · 2025: 1 · 2022: 1 · 2021: 3 · 2020: 1 · 2018: 2 · 2016: 5 · 2015: 4 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- muscle sympathetic nerve activity, sympathetic nervous system, renin-angiotensin system, plasma renin activity, plasma angiotensin II, captopril, antihypertensive therapy, arterial pressure, tibial nerve
- MeSH terms
- Adult, Angiotensin II, Blood Pressure, Captopril, Female, Heart Rate, Humans, Hypertension, Male, Renin, Sympathetic Nervous System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elevated sympathetic nerve activity in patients with accelerated essential hypertension. https://app.cochat.ai/papers/10.1172/jci116558
- The paper
- Matsukawa, T., Mano, T., Gotoh, E., & Ishii, M. (1993). Elevated sympathetic nerve activity in patients with accelerated essential hypertension. Journal of Clinical Investigation. https://doi.org/10.1172/jci116558
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

